TRACK (2026) — Trial Summary
TRACK (2026): Randomized, double-blind, placebo-controlled trial at 90 centers in 12 countries of rivaroxaban 2.5 mg twice daily versus placebo in adults with CKD stage 4 or 5 or dialysis-dependent kidney failure plus elevated cardiovascular risk (prior CAD/PAD, nonhemorrhagic nonlacunar stroke, dia
References
- Badve SV, Perkovic V, Jha V, et al; TRACK Trial Investigators. Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial. JAMA. 2026;336(4):296-305.